Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
A correction was published on 30 September 2011, see Pharmaceuticals 2011, 4(10), 1293-1294.

Pharmaceuticals 2009, 2(3), 118-124; doi:10.3390/ph2030118
Review

Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?

* ,  and
Received: 21 October 2009; in revised form: 14 November 2009 / Accepted: 17 November 2009 / Published: 27 November 2009
(This article belongs to the Special Issue Antihypertensive Drugs)
View Full-Text   |   Download PDF [41 KB, uploaded 27 November 2009]
Abstract: The renin-angiotensin-aldosterone system (RAAS) plays a dominant role in the pathophysiology of hypertension, diabetes mellitus, chronic kidney disease and chronic heart failure. Therefore, drugs that block key components of the RAAS such as ACE inhibitors (ACEI) and angiotensin receptor blockers (ARBs) have gained wide clinical use for these indications. Despite progress, the morbidity and mortality of patients treated with ACEI or ARBs remain high. Aliskiren (Tekturna, Rasilez) is the first orally active inhibitor of renin approved for clinical use as an antihypertensive agent. The development program has established that at the licensed doses of 150 mg and 300 mg. Aliskiren is effective either as monotherapy or in combination with drugs from the other major classes. In this review we analyze and review the information already gained with Aliskiren, raises questions regarding the advantages of DRIs as monotherapy compared to marketed ACEIs and ARBs, their potential added value in combination with other RAAS modulators and other still unproven benefits in relation to prorenin and renin receptor biology.
Keywords: aliskiren; RAS system; ACE inhibitors; angiotensin receptor blockers aliskiren; RAS system; ACE inhibitors; angiotensin receptor blockers
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Novo, S.; Fazio, G.; Raccuglia, E. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals 2009, 2, 118-124.

AMA Style

Novo S, Fazio G, Raccuglia E. Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors? Pharmaceuticals. 2009; 2(3):118-124.

Chicago/Turabian Style

Novo, Salvatore; Fazio, Giovanni; Raccuglia, Elena. 2009. "Aliskiren: Just a New Drug for Few Selected Patients or an Innovative Molecule Predestinated to Replace Arbs and Ace-Inhibitors?" Pharmaceuticals 2, no. 3: 118-124.


Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert